Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vor Biopharma Inc.VOR · Entity 4763 | Chief Medical Officer | February 01, 2022 | February 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vor Biopharma Inc.
Report date February 01, 2022 · Filed February 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2032-01-31 | Direct | 116,000 |
Reported balance
After 2022-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-01 · Grant · Acquired 116,000 · Balance 116,000 F1: This option vests over four years in equal monthly installments beginning on February 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests over four years in equal monthly installments beginning on February 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2022 Filed Feb 3, 2022 16:36 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 116,000 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001209191-22-006810 · doc4.xml · derivative · entry 1 Slapak Christopher · CIK 0001841150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,000 Underlying: Common Stock · 116,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: This option vests over four years in equal monthly installments beginning on February 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.